Vitamin D is 25-hydroxylated in the liver, before being activated by 1α-hydroxylation in the kidney. Recently, the rat cytochrome P450 2J3 (CYP2J3) has been identified as a principal vitamin D 25-hydroxylase in the rat (Yamasaki et al. J. Biol. Chem., 2004). In this study, we examine whether human CYP2J2 that exhibits 73% amino acid homology to rat CYP2J3 has similar catalytic properties. Recombinant human CYP2J2 was overexpressed in Escherichia coli, purified, and assayed for vitamin D 25-hydroxylation activity. We found significant 25-hydroxylation activity 
Introduction
Two vitamin D compounds, vitamin D 3 and vitamin D 2, are known to be physiologically important for calcium homeostasis [1] [2] [3] [4] [5] . Vitamin D 3 can be obtained by the light and heat conversion of 7-dehydrocholesterol in the skin or from the diet, while vitamin D 2 derived from a plant sterol, ergosterol, can only be obtained from the diet. A recent report showed vitamin D 2 is much less effective than vitamin D 3 in humans [6] .
Both vitamin D 3 and D 2 are converted into the active forms, 1,25(OH) 2 [7, 8] . In both vitamin D compounds, the hydroxylation of the side chain at C-25 or C-24 is a prerequisite for the subsequent 1α-hydroxylation controlled by physiological conditions [3, 9, 10] . Therefore, characterization of the enzymes involved in the side chain hydroxylation of vitamin D is important for understanding the whole scheme of vitamin D activation.
To date, six vitamin D 25-hydroxylases have been reported: CYP27A1, CYP2R1, CYP3A4, CYP2C11, CYP2D25, and CYP2J3 [11, 12] . CYP27A1 is a mitochondrial P450, hydroxylating at C-25 of vitamin D 3 and at C-24 of vitamin D 2 , as well as at C-27 of the intermediates of bile acid synthesis [13, 14] . The CYP27A1 gene is highly conserved in all vertebrates. However, knockout mice of the CYP27A1 gene exhibit no significant changes in vitamin D metabolism. Also, cerebrotendinous xanthomatosis patients, who have serious mutations in the CYP27A1 gene, exhibit no or little changes in the serum concentration of 25-hydroxyvitamin D compounds in spite of abnormal cholesterol metabolism [15, 16] . Therefore, CYP27A1 is thought to be critical for bile acid synthesis as a sterol 27-hydroxylase.
Recently, CYP2R1 has been identified as a novel microsomal vitamin D 25-hydroxylase by expression cloning using a CYP27A1-knockout mouse cDNA library [17] . The CYP2R1 gene is conserved in all vertebrates, and is dominantly expressed in the liver and testes of mice. The following study of Cheng et al. revealed that a patient with low circulating levels of 25-hydroxyvitamin D is homozygous for a mutation of CYP2R1 gene [18] . This findings have established the CYP2R1 is the essential vitamin D 25-hydroxylase in humans.
CYP3A4 is the most abundant P450 expressed in the adult human liver and intestine, and is involved in the metabolism of about half of the drugs in use.
Interestingly, it exhibits 25-hydroxylation activity for vitamin D 2 , but not for vitamin D 3 [19] . CYP2C11 and CYP2D25 have been purified as major microsomal vitamin D 25-hydroxylases in male rats and pigs, respectively [20] [21] [22] . CYP2C11 is a P450 specific to the male rat. In spite of the significant 25-hydroxylation activity of CYP2D25, its human ortholog, CYP2D6, shows no detectable effect on vitamin D [23] .
Thus, CYP2C11, CYP2D25, and CYP3A4 seem to be species-specific vitamin D hydroxylases.
We have recently identified CYP2J3 as a novel vitamin D 3 25-hydroxylase in rats [24] . CYP2J3 is highly expressed in the liver regardless of sex, and exhibits markedly higher (about 10 times) 25-hydroxylation activity toward vitamin D 3 than do interest to determine whether human CYP2J2, the sole human CYP2J subfamily member with 73% amino acid homology to CYP2J3, shows 25-hydroxylation activity even though CYP2R1 is the essential 25-hydroxylase in humans. Here, we prepared a recombinant human CYP2J2, and compared its catalytic activity toward vitamin D with that of rat CYP2J3. We found that CYP2J2 shows significant 25-hydroxylation activity, which suggests the contribution of the CYP2J subfamily to vitamin D metabolism.
Experimental Procedures

Materials
Vitamin D 3 was obtained from Katayama Chemical Co. (Osaka, Japan). pKSN2, was modified from pkk223-3 as previously described by Akiyoshi-Shibata et al. [25] . 25(OH)D 2 was synthesized as described [26] . Primers for polymerase chain reactions (PCR) were synthesized by Kurabo Industries Ltd. (Osaka, Japan). All other chemicals were of the highest quality commercially available. cDNA completely agreed with that of the registered CYP2J2 cDNA sequence in GenBank (accession no. U37143). The insert cDNAs were excised from the corresponding pGEM-T Easy vectors containing native or modified CYP2J2 cDNAs by digestion with Nde and Hind III. They were then purified, and subsequently ligated into the expression vector pKSN2 at the corresponding restriction sites to construct the expression plasmids (pK2J2, pKD19, and pKD34) encoding 2J2 (wild type), D19, and D34, respectively. E. coli JM109 was transformed with pK2J2, pKD19, or pKD34 for expression experiments.
Cloning of CYP2J2 cDNA and construction of N-terminal deletion mutants
Overproduction of recombinant CYP2J2 in E. coli
The E. coli cells harboring the CYP2J2 expression plasmid were transformed with pGro7 containing the GroEL-GroES gene, and selected with chloramphenicol (20 μg/ml). The doubly transformed E. coli cells were precultured in LB medium (15 ml) containing ampicillin (50 μg/ml) and chloramphenicol (20 μg/ml) at 37°C overnight, and then 1 ml of the culture was transferred into 40 ml of TB medium containing 5 mg/ml arabinose, and maintained at 37°C. Upon reaching mid-log phase (A 600 = around 0.6), the culture temperature was reduced to 28°C, and isopropyl 1-thio-β-D-galactopyranoside and δ-aminolevulinic acid were added to the final concentrations of 1 mM and 0.5 mM, respectively. The cultures were maintained for 20 h or 44 h at 28°C. The following operations except the measurement of P450 spectrum were carried out at 4°C or on ice. The cells were harvested by centrifugation, suspended in a glycerol buffer (100 mM potassium phosphate (pH 7.4), 1 mM EDTA, 1 mM dithiothreitol, and 20% glycerol), and treated with 1 mg/ml lysozyme for 1 h. After lysis, cells were disrupted by sonication and centrifuged at 500 x g for 10 min, and the supernatant was recentrifuged at 100,000 x g for 1 h. The supernatant and pellets were separated as cytosol and membrane fractions, respectively. The membrane fraction was suspended in the glycerol buffer and solubilized with 0.5% Emulgen 911 (final concentration 0.5%) for 30 min. After centrifugation at 100,000 x g for 30 min, the supernatant was collected. The cytosol and solubilized membrane fractions were subjected to the measurement of P450 contents by a reduced CO-difference-spectrum [27] .
Purification of recombinants of CYP2J2 and CYP2J3
All purification procedures were carried out at 4°C. The cells expressing D34
were grown in 600 ml of TB medium for 44 h at 28°C, and the membrane fraction was prepared as described above. After solubilization with sodium cholate (final concentration 0.5%) and centrifugation at 100,000 x g for 30 min, the supernatant was loaded onto an ω-aminohexyl Sepharose column (1.6 x 3.0 cm) equilibrated with buffer A (10 mM potassium phosphate (pH 7.4), 1 mM EDTA, 1 mM dithiothreitol, 20% glycerol, and 0.5% cholate). The column was washed with 2 column volumes of buffer A, and proteins were eluted stepwise with the same buffers containing 0.1% and 0.5% Emulgen 911. The eluted fractions (0.5% Emulgen) containing P450 were pooled, and dialyzed against buffer B (10 mM potassium phosphate (pH 7.4), 1 mM EDTA, 1 mM dithiothreitol, 20% glycerol, and 0.3% cholate) overnight. The dialyzed fractions were loaded onto a hydroxyapatite column (1.6 x 2.0 cm) equilibrated with buffer B, and washed with more than 100 ml of buffer B to remove Emulgen 911 completely. Proteins were eluted stepwise with buffer B containing 100 mM, 150 mM, and 500 mM potassium phosphate (pH 7.4). The fractions (500 mM eluate) containing P450 were dialyzed against buffer B and loaded onto a DEAE-Sepharose column (1.6 x 3.0 cm) equilibrated with buffer B. The column was washed with buffer B and P450 was eluted stepwise with buffer B containing 100 mM and 150 mM potassium phosphate (pH 7.4).
The P450 fraction (150 mM eluate) was dialyzed against buffer C (10 mM potassium phosphate (pH 7.4), 1 mM EDTA, 1 mM dithiothreitol, 20% glycerol, and 0.05% cholate) and stored at -80°C. The N-terminal deletion mutant CYP2J3 (dN2J3) was expressed in E. coli and purified as described previously [24] . The final preparations were analyzed for their purity by 10% SDS-polyacrylamide gel electrophoresis according to the method of Laemmli [28] . Protein concentrations were determined by the BCA protein assay kit (Pierce).
Assay of vitamin D 25-hydroxylase activity
Assay methods were described previously [29] . Briefly, the purified P450 
Mass spectrometric analysis of the metabolites
Metabolites were purified by the normal and reverse phase HPLC. The isolated products were dissolved in ethanol (50 μl) and infused via a syringe pump (Holliston, Ma, USA) at 10 μl/min into the ionspray source of an Applied Biosystems/QSTAR XL (Concord, Ontario, Canada) triple quadrupole instrument. The collision gas was nitrogen and the instrument was optimized for maximum response at unit mass resolution. The data were averaged over 100 scans collected in duplicate.
Results
Heterologous expression of human CYP2J2 in E. coli
We have prepared three CYP2J2 expression vectors, for a full-length protein (2J2) as well as for two N-terminal deletion mutant proteins (D19 and D34), as shown in Fig. 1 , since substitutions and/or deletions of the N-terminal hydrophobic region (membrane anchor region) of microsomal P450 improve expression in E. coli [30] . 2J2 has one Leu (CTC) to Ala (GCT) substitution at the second codon, as is also the case for CYP17 [31] . D19 lacks half of a putative membrane anchor region, and the N-terminal sequence is modified similarly to that of a CYP3A4 mutant [32] . D34 was completely devoid of the N-terminal hydrophobic region, with the new N-terminal region modified like that of the CYP2J3 mutant [24] . In spite of these modifications, none of the constructs expressed P450 when analyzed by CO-difference spectra. Since CYP2J3 expression was markedly improved by the co-expression of E. coli chaperone proteins [24] , we applied the same strategy to CYP2J2 expression experiments. Co-expression of GroEL-GroES dramatically increased the expression levels of the P450 (Fig. 2 and Table 1) . The P450 expression level of E. coli cells containing pKD34/pGro7 was more than 100 times higher than of those containing pKD19/pGro7. D34 was distributed both in cytosol and membrane fractions equally, whereas D19 predominantly localized in the membrane fraction. Long culture times (44 h) did not increase the P450 level (Table 1) .
Purification of D34
D34 was purified from the membrane fraction because of its higher P450 content therein relative to the cytosol fraction ( Table 1 ). The membrane fraction was solubilized and applied to hydrophobic and subsequent hydroxyapatite column chromatographies. In the hydroxyapatite column step, Emulgen 911 was completely removed by extensive washing (while monitoring its UV absorption at 275 nm), since it significantly inhibits the vitamin D hydroxylation activity of CYP2J2 (data not shown).
Finally, samples were subjected to a DEAE-Sepharose column for purification and concentration, and dialyzed against a buffer (containing 0.05% cholate) that did not inhibit vitamin D 25-hydroxylase activity. SDS-polyacrylamide gel electrophoresis of the final preparations showed single major bands with the predicted molecular weights (Fig. 3) . The P450 contents of D34 and dN2J3 (recombinant CYP2J3) were more than 10 nmol P450/mg proteins.
Analysis of 25-hydroxylation activities of CYP2J enzymes
Vitamin D 25-hydroxylation assays were carried out using a reconstituted system consisting of NADPH-P450 reductase. The products were analyzed by comparison of their retention times with authentic 25-hydroxylated compounds, as described in Experimental Procedures. (Table 3). CYP2J2 showed no 1α-, 24-, and 26-hydroxylation activity toward 25(OH)D 3 , and no 2α-and 16α-hydroxylation activity toward testosterone, indicating similar enzymatic characteristics to CYP2J3 (data not shown). Ebastin, a histamine H1-receptor antagonist, is a well-characterized drug that is metabolized to pharmacologically active metabolite via the hydroxylation catalyzed by CYP2J2 or CYP2J3 in the intestine [33] . The activity of CYP2J2 and CYP2J3 toward vitamin D was lower compared to that toward ebastin (Table 3 ).
Discussion
We have analyzed the vitamin D 25-hydroxylation activity of human CYP2J2 and compared it with that of the rat's orthologous P450, CYP2J3, since CYP2J3 shows markedly high 25-hydroxylation activity toward vitamin D 3 , and appears to play an important role as a vitamin D 25-hydroxylase in the rat's liver [24] . Here, we have clearly demonstrated that human CYP2J2 also exhibits significant 25-hydroxylation activity for vitamin D 3 , even though human CYP2J2 and rat CYP2J3 show a 27% amino acid sequence difference. Interestingly, human CYP2J2 exhibited twofold higher hydroxylation activity for vitamin D 2 than for vitamin D 3 . This preference was opposite to that of the rat CYP2J3 (Table 3) . Therefore, human and rat CYP2J proteins exhibit distinct preferences for vitamin D compounds.
CYP2J2 has a high catalytic ability for drugs and xenobiotics such as ebastin [33] , in keeping with the present observation that CYP2J2 prefers vitamin D 2 (exogenous) to vitamin D 3 (endogenous). However, when the same amount of vitamin D 2 and D 3 is orally administered, rats exhibits a higher blood-concentration of 25(OH)D 2 , whereas humans show a higher concentration of 25(OH)D 3 [6, 34, 35] . These results are opposite to those one would predict from the 25-hydroxylation preferences of CYP2J2 and CYP2J3. Therefore, the serum 25(OH)D status is likely to be determined by several factors, such as the substrate specificity of other 25-hydroxylases, affinity for vitamin D binding protein, clearance rates, and absorption efficiencies in the intestine.
Humans express two microsomal P450's (CYP2R1 [17] and CYP3A4 [19] ) and a mitochondrial P450 (CYP27A1 [13] ) that exhibit vitamin D 25-hydroxylation activity. CYP2R1 is mainly expressed in the liver and testis, and hydroxylates both vitamin D 3 on the expression experiments of CYP2R1 cDNA using HEK 293 cells [18] .
CYP3A4, a major P450 involved in xenobiotics metabolism in the liver and intestine, shows 25-hydroxylation activity for vitamin D 2 but not for vitamin D 3 [19] .
CYP27A1 is expressed ubiquitously [36, 37] , and exhibits 25-hydroxylation activity toward vitamin D 3 and 24-hydroxylation activity toward vitamin D 2 [13] . Our results have demonstrated that CYP2J2 exhibits a relatively higher 25-hydroxylation activity for vitamin D 2 than for vitamin D 3 . It localizes in the intestine, liver, and heart [38] . Therefore, it is likely that, similar to xenobiotics, vitamin D 2 undergoes a first-pass activation in the intestine by CYP2J2 or CYP3A4 [39] analyze its catalytic properties [33, 38] , no expression experiment of CYP2J2 in E. coli has been reported. Our E. coli expression system has achieved a very high expression level of CYP2J2 by combining the deletion of a putative membrane anchor region in the N-terminal with the co-expression of the E. coli chaperone protein GroEL-GroES (Table   1) . Therefore, the modification applied here is useful for the preparation of CYP2J2 protein. It should be noted that the truncations of the N-terminal hydrophobic region do not severely affect the catalytic activity and substrate specificity of P450 [24, 40] . The deletion of an N-terminal hydrophobic region may account for the equal distribution of D34 in cytosol and membrane fractions (Table 1) 
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